News Rising UK drugs bill raises fears of price controls Higher than expected growth in the branded medicines bill has caused the UK government to consider price cuts.
News A vote of no confidence in UK's pricing system The new PPRS is not good news for all pharma companies, concludes industry audience
News Just how radical is the FDA's complete response letter move? The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
